Skip to main content
. Author manuscript; available in PMC: 2017 Feb 9.
Published in final edited form as: Invest New Drugs. 2010 Aug 10;30(1):258–265. doi: 10.1007/s10637-010-9504-5

Fig. 1.

Fig. 1

MRI imaging with conventional (top row) and perfusion (bottom row) sequences in a patient with uterine leiomyosarcoma showing variable microvascular permeability (Ktrans) at baseline (left), cycle 1 day 10 (middle), and on cycle 2 day 3 (right) of therapy